This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. (currently amended) ~~Use of the compounds of the following formula (I)~~ A method for the treatment of postlesional diseases of ischemic, traumatic or toxic origin, comprising administering an effective amount of a compound of formula (I):




wherein X represents OH, $(C_{1-5})$alkoxy, $NH_2$, NH-$C_{1-5}$-alkyl, or $N(C_{1-5}$ alkyl$)_2$;

$R_1$ is a residue derived from any of the amino acids Phe, Tyr, Trp, Pro, each of which may optionally be substituted by a $(C_{1-5})$ alkoxy group, a $(C_{1-5})$ alkyl group or a halogen atom, and Ala, Val, Leu, or Ile;

$R_2$ is a residue which is derived from any of the amino acids Gly, Ala, Ile, Val, Ser, Thr, His, Arg, Lys, Pro, Glu, Gln, pGlu, Asp, Leu ~~and~~ or Asn;

$R_3$ and $R_4$ independently represent H, OH, $(C_1$-$C_5)$alkyl, or $(C_{1-5})$alkoxy, provided that $R_3$ and $R_4$ are not both OH or $(C_{1-5})$alkoxy;

$R_5$ represents H, OH, $(C_{1-5})$ alkyl or $(C_{1-5})$alkoxy;

and wherein $R_0$ represents a group of the formula




wherein Y represents -CO-, -$CH_2$CO-, -$CH_2CH_2$CO-, -$CH_2CH_2CH_2$CO-, -CH=CH-CO or -$OCH_2$CO-, and wherein Z represents a halogen atom, a trifluormethyl group, ($C_{1-4}$) alkoxy group, ($C_{1-4}$) alkyl group; or wherein two neighboring substituents may form a ($C_{1-3}$) alkylendioxy group; and wherein n is 0 or an integer of from 1 to 5;
or pharmaceutically acceptable salts thereof~~;~~ .
~~for the preparation of a medicament useful in the treatment of postlesional diseases of ischemic, traumatic or toxic origin.~~

2. (currently amended) The ~~use~~ method according to claim 1, wherein $R_1$ is a residue derived from any of the amino acids Phe, Tyr, Trp, each of which may optionally be substituted by a ($C_{1-5}$) alkoxy group, a ($C_{1-5}$) alkyl group or a halogen atom, or a residue derived from the amino acid Ile.

3. (currently amended) The ~~use~~ method according to claim 2, wherein $R_1$ is a residue derived from Phe which may optionally be substituted by a ($C_{1-5}$) alkoxy group, a ($C_{1-5}$) alkyl group or a halogen atom.

4. (currently amended) The ~~use~~ method according to ~~any of the preceding claims~~ claim 1, wherein X is ($C_{1-5}$) alkoxy, $NH_2$, NH-$C_{1-5}$ alkyl, or N($C_{1-5}$ alkyl)$_2$.

5. (currently amended) The ~~use~~ method according to ~~any of the preceding claims~~ claim 1, wherein $R_2$ is a residue derived from the amino acid Gly or Ile.

6. (currently amended) The ~~use~~ method according to ~~any of the preceding claims~~ claim 1, wherein $R_0$ is a cinnamoyl moiety.

7. (currently amended) The ~~use~~ method according to ~~any of the preceding claims~~ claim 1, wherein the compound of formula (I) is cinnamoyl-glycyl-Lphenylalanyl-L-prolinamide, cinnamoyl-isoleucyl-phenylalanyl-L-proline ethylamide, cinnamoyl-isoleucyl-isoleucyl-prolineamide, or a pharmaceutically acceptable salt thereof.